Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise

Cancer in newspaper clipping
Tyra Biosciences is aiming for drivers of drug-resistant tumors to come up with new drugs that work against the mutated, or resistant, form of a protein, as well as the original form of the protein. (PDPics/Pixabay)

Targeted therapies have changed the face of treatment for many cancers, such as those with EGFR or ALK mutations. But over time, tumors rewire themselves to find a way around these therapies and continue to grow without relying on proteins made by the mutated gene. 

Tyra Biosciences is taking aim at this rewiring, called acquired resistance, banking $50 million in its series A round to get on its way. The Carlsbad, California-based biotech will develop a pipeline of “very specific” small molecules to target drug-resistant cancer cells. 

“Acquired resistance has a connotation that is a little bit more specific than just relapse more broadly,” Todd Harris, Tyra’s CEO and co-founder, told FierceBiotech. “We talk about it in the context of targeted therapies. When tumors resist targeted therapies, there is often a really specific molecular driver or event that has occurred to induce that resistance.” 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

RELATED: Two-pronged attack against lung cancer could overcome EGFR drug resistance

Tyra is zeroing in on those drivers to come up with new drugs that work against the mutated, or resistant, form of a protein, as well as the original form of the protein against which targeted drugs were made, Harris said. It’s doing so with a team of experienced drug hunters and advisers who have collectively brought more than 20 compounds into the clinic, he said. 

They will have many leads to chase. In addition to resistance-driving signaling pathways Tyra already knows about, more are turning up all the time. 

"Insights are emerging in real time … On a yearly, if not monthly basis, we are learning more about mutations popping up in patients in the clinic that need to be addressed,” Harris said. 

The funding, from Alta Partners, RA Capital, Boxer Capital of Tavistock Group and Canaan Partners, will support the company through a “near-term value inflection point,” Harris said. 

“We’re not describing specific dates yet, but the amount of capital certainly gives us runway to take our first drug all the way through into patients and into proof-of-concept studies to validate it,” he said.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.